Point Biopharma Global Inc Expected To Post A Loss Of 21 Cents A Share: Earnings Preview

POINT Biopharma Global

11/05/2022 13:57

* POINT Biopharma Global Inc  PNT.OQ   PNT.O  is expected
to report results on May 13.
    * ​Refinitiv's mean analyst estimate for POINT Biopharma
Global
Inc is for a loss of 21 cents per share. 
    * The current average analyst rating on the shares is "buy"
and
the breakdown of recommendations is 3 "strong buy" or "buy," 1
"hold" and no "sell" or "strong sell."  
    * The mean earnings estimate of analysts had risen by
about 0.7%
in the last three months. ​
    * Wall Street's median 12-month price target for POINT
Biopharma
Global Inc is $17​, above​ its last closing price of $6.09. ​​​
    * Previous quarterly performance (using preferred earnings
measure
in US dollars). ​

 QUARTER       STARMINESM  REFINITIV  ACTUAL    BEAT,   SURPRI
 ENDING        ARTESTIMAT  IBES                 MET,    SE %
               E®          ESTIMATE             MISSED  
 Dec. 31 2021  -0.22       -0.23      -0.16     Beat    31.9
 Sep. 30 2021  -0.19       -0.19      -0.19     Met     -1.8
 Jun. 30 2021  -0.11       -0.11      -0.15     Missed  -36.4​
 ​​                                                     
                                                        ​
 This summary was machine generated May 11 at 12:57 GMT.  All
figures in US dollars  unless otherwise stated